Equity Overview
Price & Market Data
Price: $14.72
Daily Change: -$0.35 / 2.38%
Range: $13.96 - $20.50
Market Cap: $2,500,353,792
Volume: 1,149,053
Performance Metrics
1 Week: -2.84%
1 Month: -17.72%
3 Months: -36.14%
6 Months: -50.27%
1 Year: -48.55%
YTD: -40.57%
Company Details
Employees: 207
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. The company develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, Graves diseases, and warm autoimmune hemolytic anemia. Immunovant, Inc. is based in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.